Ardelyx (ARDX) vs Candel Therapeutics (CADL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Candel Therapeutics (CADL) has outperformed Ardelyx (ARDX) over the past year, gaining 53.3% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with -1.7% for CADL. Ardelyx is the larger company by market cap ($839.1 million vs $739.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | CADL |
|---|---|---|
| Share price | $3.25 | $9.67 |
| Market cap | $839.11M | $739.93M |
| 1-day change | -0.61% | +0.10% |
| YTD return | -43.91% | +70.97% |
| 1-year return | -35.38% | +53.33% |
| 5-year return | +202.78% | -1.73% |
| Forward P/E | 11.19 | — |
| EPS (TTM) | $-0.23 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $14.00 |
| 52-week low | $3.18 | $4.35 |
| Distance from 52-week high | -61.31% | -30.93% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +296.92% | +124.92% |
| Average volume | 4.17M | 1.21M |
| Shares outstanding | 258.19M | 76.52M |
| Employees | 489 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed ARDX by 88.7 percentage points over the past year.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
ARDX vs CADL FAQ
Which is bigger, Ardelyx or Candel Therapeutics?
Ardelyx (ARDX) is larger, with a market capitalization of $839.11M compared with $739.93M for Candel Therapeutics (CADL).
Which stock has performed better over the past year, ARDX or CADL?
CADL returned +53.33% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Candel Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Ardelyx and Biotechnology: Biological Products (No Diagnostic Substances) for Candel Therapeutics.